Vericel Corporation is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The company markets two FDA-approved autologous cell therapy products—MACI (a cellularized scaffold for knee cartilage repair) and Epicel (a permanent skin replacement for severe burns)—and one FDA-approved specialty biologic product, NexoBrid (a topically-administered enzyme product for eschar removal in thermal burns). Vericel operates a cell manufacturing facility in Cambridge, Massachusetts, and a new manufacturing and laboratory facility in Burlington, Massachusetts, designed to become the primary manufacturing site for MACI and Epicel.
expected 2027-02-04
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001628280-26-012013 | EDGAR | 68K words |
| 2025-02-27 | 2024-12-31 | 0001628280-25-008447 | EDGAR | 68K words |
| 2024-02-29 | 2023-12-31 | 0001628280-24-007824 | EDGAR | 68K words |
| 2023-02-23 | 2022-12-31 | 0001628280-23-004714 | EDGAR | 72K words |
| 2022-02-24 | 2021-12-31 | 0001628280-22-003661 | EDGAR | 73K words |
| 2021-02-24 | 2020-12-31 | 0001628280-21-003081 | EDGAR | 73K words |
| 2020-02-25 | 2019-12-31 | 0001628280-20-002229 | EDGAR | 66K words |
| 2019-02-26 | 2018-12-31 | 0001628280-19-002007 | EDGAR | 63K words |
| 2018-03-05 | 2017-12-31 | 0001628280-18-002753 | EDGAR | 62K words |
| 2017-03-13 | 2016-12-31 | 0001628280-17-002492 | EDGAR | 68K words |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-11-05 | 2026-09-30 | 0001628280-26-070657 | EDGAR | 17K words |
| 2026-07-30 | 2026-06-30 | 0001628280-26-050836 | EDGAR | 16K words |
| 2025-11-06 | 2025-09-30 | 0001628280-25-049902 | EDGAR | 17K words |
| 2025-07-31 | 2025-06-30 | 0001628280-25-036859 | EDGAR | 17K words |
| 2025-05-08 | 2025-03-31 | 0001628280-25-023496 | EDGAR | 16K words |
| 2024-11-07 | 2024-09-30 | 0001628280-24-046015 | EDGAR | 16K words |
| 2024-08-01 | 2024-06-30 | 0001628280-24-033905 | EDGAR | 16K words |
| 2024-05-08 | 2024-03-31 | 0001628280-24-021399 | EDGAR | 16K words |
| 2023-11-08 | 2023-09-30 | 0001628280-23-037583 | EDGAR | 22K words |
| 2023-08-02 | 2023-06-30 | 0001628280-23-026596 | EDGAR | 21K words |
| 2023-05-10 | 2023-03-31 | 0001628280-23-017039 | EDGAR | 19K words |
| 2022-11-09 | 2022-09-30 | 0001628280-22-029082 | EDGAR | 96K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-11-05 | 0001628280-26-070622 | EDGAR | 3K words |
| 2026-07-30 | 0001628280-26-050815 | EDGAR | 3K words |
| 2026-02-26 | 0001628280-26-012003 | EDGAR | 3K words |
| 2026-01-13 | 0001140361-26-001060 | EDGAR | 2K words |
| 2025-11-06 | 0001628280-25-049880 | EDGAR | 3K words |
| 2025-07-31 | 0001628280-25-036854 | EDGAR | 3K words |
| 2025-05-08 | 0001628280-25-023481 | EDGAR | 3K words |
| 2025-05-02 | 0001140361-25-017110 | EDGAR | 11K words |
| 2025-04-14 | 0001140361-25-013625 | EDGAR | 1K words |
| 2025-02-27 | 0001628280-25-008444 | EDGAR | 4K words |
295 total filings indexed. 263 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0000887359 |
| Ticker | VCEL |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | MI |
| Headquarters | Cambridge, Massachusetts |
| Website | https://www.vcel.com |
| Listed | 1997-02-04 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/VCEL (~200 tokens, structured JSON with cryptographic provenance)